Rodriguez Julie, Cordaillat-Simmons Magali, Pot Bruno, Druart Céline
Pharmabiotic Research Institute (PRI), Narbonne, France.
Research Group of Industrial Microbiology and Food Biotechnology (IMDO), Faculty of Sciences and Bioengineering Sciences, Vrije Universiteit Brussel, Brussels, Belgium.
NPJ Biofilms Microbiomes. 2025 Mar 28;11(1):53. doi: 10.1038/s41522-025-00683-0.
The emergence of a broad spectrum of microbiome-based therapies has triggered changes in European regulatory frameworks. The first part of the review describes these innovative therapies. The second part provides an overview of the current framework and key changes introduced by the Regulation on substances of human origin (SoHO) for the development of microbiome-based therapies, highlighting the need of microbiome regulatory science to unlock the full potential of microbiome-based therapies.
多种基于微生物群的疗法的出现引发了欧洲监管框架的变革。综述的第一部分描述了这些创新疗法。第二部分概述了当前框架以及《人类源物质(SoHO)条例》为基于微生物群的疗法开发引入的关键变化,强调了微生物群监管科学对于释放基于微生物群的疗法全部潜力的必要性。